Program
HS-10374
A development code. Also written as “HS-10374 tablets”, “HS-10374 6mg tablets” and “HS-10374 tablets 1mg”.
In Hansoh Pharmaceutical Group's pipeline, TYK2
. Its studies are mostly in Psoriasis · Arthritis, Psoriatic, led by Hansoh Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 64 open or running | phase 3since Oct 31, 2024 | Aug 24, 2023 | none ahead |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-10374 (TYK2)
, phase 2, as of Aug 26, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 24, 2023First study: phase 2 study in PsoriasisFirst studyNCT06077331 · 120 planned · China
- Aug 24, 2023Phase 1 study in PsoriasisNCT06033742 · 84 enrolled · China
- Dec 8, 2023Phase 2 study in Arthritis, PsoriaticNCT06176508 · 160 planned · China
- Oct 31, 2024Phase 3 study in PsoriasisNCT06672393 · 375 planned · China
- Apr 10, 2025Phase 2 study in PsoriasisNCT06926582 · 305 planned · China
- Aug 20, 2025Phase 1 study in PsoriasisNCT07181343 · 18 enrolled · China
TargetBeta
“TYK2”the company's pipeline, read by Claude · source
Other programs on TYK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| deucravacitinibrule | Bristol-Myers Squibb | phase 4 | 60 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| D-2570rule | InventisBio | phase 3 | 13 |
| TQH3906 | Sino Biopharmaceutical | phase 3 | 6 |
| FXS5626 | Fosun Pharma | phase 3 | 3 |
| TYK2 Inhibitorrule | usynova-pharmaceuticals-ltd | no phase | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07181343Psoriasis · China | 1 | Completed | Jun 17, 2025 | 18 |
| NCT06926582Psoriasis · China | 2 | Not yet recruiting | Jul 9, 2026 | 305 |
| NCT06672393Psoriasis · China | 3 | Not yet recruiting | Oct 22, 2025 | 375 |
| NCT06176508Arthritis, Psoriatic · China | 2 | Recruiting | Apr 28, 2026 | 160 |
| NCT06077331Psoriasis · China | 2 | Recruiting | Jul 31, 2024 | 120 |
| NCT06033742Psoriasis · China | 1 | Completed | Mar 24, 2023 | 84 |
How it is read
Names in the registry
- “HS-10374 tablets”, 2 entries
- “HS-10374 6mg tablets”, 2 entries
- “HS-10374”, 1 entry
- “HS-10374 tablets 1mg”, 1 entry
- “HS-10374 tablets 5mg”, 1 entry
Codes read as this program: HS10374.
Conditions, from the studies’ own filings
- Psoriasis, 5 studies
- Arthritis, Psoriatic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.